Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madhumita Shrotri

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Nature Reviews. Rheumatology|June 19, 2026
TLR7 in systemic lupus erythematosus: genetics and emerging therapiesCarola G Vinuesa, Madhumita Shrotri, Anisur Rahman
Influenza and Other Respiratory Viruses|August 9, 2020
Horses for courses? Assessing the potential value of a surrogate, point-of-care test for SARS-CoV-2 epidemic controlSharif A Ismail, Catherine Huntley, Nathan Post, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 19, 2021
Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021Rebecca Giddings, Maria Krutikov, Tom Palmer, et al.
Age and Ageing|August 18, 2023
Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI studyOliver Stirrup, Madhumita Shrotri, Natalie L Adams, et al.
The Lancet. Healthy Longevity|June 9, 2021
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort studyMaria Krutikov, Tom Palmer, Gokhan Tut, et al.
Emerging Infectious Diseases|March 18, 2021
Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UKMadhumita Shrotri, Ross J Harris, Alison Rodger, et al.
The Lancet. Healthy Longevity|July 11, 2022
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort studyMadhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity|May 9, 2022
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort studyMaria Krutikov, Oliver Stirrup, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity|December 22, 2021
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in EnglandMaria Krutikov, Tom Palmer, Gokhan Tut, et al.
The Lancet. Infectious Diseases|June 26, 2021
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort studyMadhumita Shrotri, Maria Krutikov, Tom Palmer, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Nature Reviews. Rheumatology|June 19, 2026
TLR7 in systemic lupus erythematosus: genetics and emerging therapiesCarola G Vinuesa, Madhumita Shrotri, Anisur Rahman
Influenza and Other Respiratory Viruses|August 9, 2020
Horses for courses? Assessing the potential value of a surrogate, point-of-care test for SARS-CoV-2 epidemic controlSharif A Ismail, Catherine Huntley, Nathan Post, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 19, 2021
Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021Rebecca Giddings, Maria Krutikov, Tom Palmer, et al.
Age and Ageing|August 18, 2023
Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI studyOliver Stirrup, Madhumita Shrotri, Natalie L Adams, et al.
The Lancet. Healthy Longevity|June 9, 2021
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort studyMaria Krutikov, Tom Palmer, Gokhan Tut, et al.
Emerging Infectious Diseases|March 18, 2021
Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UKMadhumita Shrotri, Ross J Harris, Alison Rodger, et al.
The Lancet. Healthy Longevity|July 11, 2022
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort studyMadhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity|May 9, 2022
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort studyMaria Krutikov, Oliver Stirrup, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity|December 22, 2021
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in EnglandMaria Krutikov, Tom Palmer, Gokhan Tut, et al.
The Lancet. Infectious Diseases|June 26, 2021
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort studyMadhumita Shrotri, Maria Krutikov, Tom Palmer, et al.
Pageof 4